Find out whether you are eligible for COVID-19 treatments or participation in a UK-wide antiviral study.
Only some people are currently eligible to receive the range of new treatment options within the community. These will be made available to NHS patients at greater risk from COVID-19.
These treatments are a further measure in addition to vaccinations. Vaccinations remain of greatest importance to protect those most vulnerable in the UK.
These treatments include oral antiviral Lagevrio and neutralising monoclonal antibody treatments Ronapreve and Xevudy.
There are 2 ways in which you can receive antiviral treatments:
- as part of your standard care if you are at highest risk of severe COVID-19 and extremely vulnerable
- through a UK wide antiviral study called PANORAMIC.
Those at highest risk of severe COVID-19 and extremely vulnerable
Some people are at particularly high risk of severe COVID-19. This includes people with:
- renal or liver disease
- Down’s syndrome
- sickle cell disease
- people who have had a transplant
- have HIV
- have a rare neurological condition (such as multiple sclerosis, Huntington’s disease, motor neurone disease or myasthenia gravis)
- or whose immune system is impaired
If you are in this group and you test positive for COVID-19 with a PCR test, you may be eligible for these treatments.
Treatments need to start within five days of symptoms. They will help manage your symptoms and reduce the risk of you becoming unwell.
If a PCR test shows positive, a healthcare professional may contact you. They will arrange an appointment to decide whether treatment is suitable for you.
In most cases the treatment offered is with a neutralising monoclonal antibody (either Ronapreve or Xevudy). You will need to attend a hospital to receive treatment. In some cases it may be more appropriate to receive Lagevrio. This comes in the form of capsules. You will need to take four capsules twice a day for five days. A clinician will discuss what is most appropriate for you.
People aged over 50 or over 18 with a health condition
You may be eligible to participate in the UK antiviral treatment study called PANORAMIC.
The PANORAMIC study looks into the use of antiviral tablets to:
- reduce the severity of the virus
- speed up recovery
- avoid the need for treatments in hospital
The medication has already been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). This study will provide more data on how antivirals work in a predominantly vaccinated population. It will inform decisions in the future.
You may be eligible if you meet all of the following criteria:
- you are over 50 or 18-49 with a health condition that means you’re vulnerable (but not eligible for antiviral treatment as part of your standard care)
- you’ve had a positive COVID-19 test (PCR or LFT)
- you’ve had COVID-19 symptoms for less than 5 days
If you meet all three criteria, go to the PANORAMIC study website or call 08081 560017(calls are free of charge).
You will also receive a text from Health and Care Research Wales with a link to the trial website if you test positive.
More information about what to expect from the study in Wales can be found on the Health and Care Research Wales website.
If you do not meet the criteria above, you may still be eligible to participate in a UK study of other COVID-19 treatments. This is through the PRINCIPLE study.
You may be eligible if:
- you are aged 18 or over
- you’ve had a positive COVID-19 test in the last 14 days
- you’ve had COVID-19 symptoms for less than 14 days
If you meet all 3 criteria, go to the Principle study website.